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Purpose: Growing evidence is showing a role of neurogenic inflammation in allergic reactions, with sensory and
autonomic nerve fibers releasing neuromediators, which may actively participate in the allergic inflammatory cascade.
Although the cornea is the most densely innervated tissue of the human body, little is known on the role of neuromediators
at the ocular surface. In this study, we aimed at evaluating the role of substance P (SP), calcitonine gene related peptide
(CGRP), neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) in allergic reactions of the ocular surface.
Methods: Fifteen patients with allergic conjunctivitis (6 female, 9 male, mean age 30±8 years) in non-active phase, and
10 age-matched healthy subjects were included in this study. The conjunctival provocation test (CPT) with allergen was
performed in all allergic patients and in 5 healthy subjects. Tear samples were collected and the tear content of VIP, NPY,
CGRP, and SP was measured by ELISA at baseline and after CPT. The Mann–Whitney U-test and Wilcoxon test were
used to compare neuromediator tear levels.
Results: No significant differences in neuropeptide tear levels were observed between healthy and allergic patients in
non-active phase. CPT induced conjunctival hyperemia and itching in all allergic patients, while no reaction was observed
in the control eyes and in healthy subjects. In allergic patients SP, CGRP, and VIP, but not NPY, were significantly higher
after CPT as compared to baseline (SP: 3.9±1.3 ng/ml versus 5.8±1.1 ng/ml, p=0.011; CGRP: 5.5±2.3 ng/ml versus 7.3±2.7
ng/ml; p=0.002; VIP: 4±0.9 ng/ml versus 5.1±1.5 ng/ml, p=0.007). No significant changes were observed in the control
eyes of allergic patients challenged with diluent and in healthy subjects after allergen provocation.
Conclusions: Locally-released neuromediators may participate in modulating the allergic response of the ocular surface.
Growing evidence is showing that allergic reactions are
influenced  by  the  peripheral  nervous  system  through  the
release  of  neuromediators  including  substance  P  (SP),
neuropeptide Y (NPY), vasoactive intestinal peptide (VIP),
and calcitonine gene-related peptide (CGRP) [1-5]. It has been
widely demonstrated that SP, NPY, and CGRP are released
from nerve endings at inflammatory sites and, more recently,
a role of VIP at the sites of neurogenic inflammation has also
been demonstrated in both animal models and humans [6-9].
In the airways, this neurogenic inflammation results in the
release  of  neuropeptides  by  nerve  endings,  triggering  the
allergic reaction with bronchoconstriction, mucus secretion
and  mucosal  hyperemia  [10-12].  Specifically,  it  has  been
described that SP is released during allergen challenge in
patients with allergic asthma and rhinitis, stimulating mucous
secretion  and  histamine  release  by  mast  cells,  enhancing
migration  and  cytotoxic  activity  of  eosinophils,  and
stimulating  T-cell  proliferation  [13-17].  In  line  with  this
evidence,  CGRP  and  VIP  have  been  shown  to  induce
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vasodilatation  and  mucus  secretion,  to  increase  vascular
permeability, and to stimulate leukocyte extravasation [18,
19].  Moreover,  VIP  and  NPY  are  known  to  play  an
immunomodulatory role by inducing T helper (Th2)- and
inhibiting Th1-reactions [20,21].
While specific roles of different neuropeptides have been
identified in allergic airway diseases, fewer data are currently
available for ocular surface diseases. The ocular surface is a
complex  morphofunctional  unit  constituted  by  cornea,
conjunctiva,  lacrimal  glands,  and  tear  film  [22].  During
allergic inflammation, all these structures are activated and
cross-talk through the release of cytokines and inflammatory
mediators. A role of neuropeptides in this cross-talk has been
recently suggested [1,4].
In line with this hypothesis, an increase of SP tear and
plasma levels and an altered VIP and SP expression in the
conjunctiva  have  been  described  in  patients  with  vernal
keratoconjunctivitis (VKC), a severe ocular allergic disease
mainly affecting young boys [23-25]. Increased levels of SP
have also been detected in tears of patients with seasonal
allergic conjunctivitis, suggesting that SP may contribute to
the pathogenesis and severity of disease [23]. Nevertheless,
to date little is known on the role of neuropeptides in the ocular
allergic reaction.
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47In this study we aimed at evaluating tear levels of SP,
CGRP, NPY, and VIP in healthy and allergic subjects at
baseline  and  after  conjunctival  allergen  provocation  test
(CPT) [26].
METHODS
Fifteen  asymptomatic  patients  previously  diagnosed  with
allergic conjunctivitis (6 females, 9 males, mean age 30±8
years) and 10 healthy subjects (3 females, 7 males, mean age
30±15  years)  were  included  in  the  study.  The  study  was
performed  following  the  tenants  of  the  Declaration  of
Helsinky. Informed consent was signed by all participants and
the  study  was  approved  by  the  internal  review  board.
Demographic and clinical characteristics of the patients in this
study are summarized in Table 1.
Diagnosis of allergic conjunctivitis was based on clinical
history, clinical examination, skin prick test and a positive
conjunctival reaction following specific allergen challenge.
Demographic, ophthalmological, and allergic history, as well
as data on concomitant systemic and ocular medications used
by the patients were collected at the inclusion visit. No signs
and/or symptoms of allergic conjunctivitis were present at the
time of inclusion in the study. Contact lens wearers and/or
patients taking any topic and/or systemic anti-allergic drugs
or steroids were excluded.
Skin prick test was performed in all allergic patients and
healthy  subjects  with  the  same  allergens  used  for  CPT
(Dermatophagoides  spp,  Graminacee,  and  Parietaria-Alk
Abellò, Milan, Italy) to confirm the presence/absence of an
allergic reaction. The allergen triggering the greatest allergic
response in the skinprick test was chosen for the following
CPT.  CPT  was  performed  according  to  a  standardized
procedure  (Alk-Abellò,  Milan,  Italy).  Briefly,  increasing
concentrations (0.001, 0.01, 0.1, 1.0, and 10.0 BU/ml) of
antigen  (Dermatophagoides  spp,  Graminacee,  or
Parietaria) were instilled into the conjunctival sac of the right
eye every 15 min. Diluent alone was instilled in the left eye,
used as control. Redness, itching and tearing were scored from
0 to 3 (0=absent, 1=mild, 2=moderate, 3=intense) and the sum
was defined as the total CPT score (from 0 to 9). When a total
CPT score ≥3 (with a score of conjunctival hyperemia of at
least 2 and itching score of at least 1) was reached, allergen
provocation was discontinued and the reaction was considered
positive. The threshold dose was defined as the minimum
allergen concentration required to obtain a positive reaction
to CPT.
Five  healthy  patients  were  also  challenged  with
Dermatophagoides  sp  (n=1)  Graminacee  (n=2),  and
Parietaria  (n=2)  and  used  as  controls  for  non  specific
reactions caused by the allergen extract.
Tear samples were collected in allergic patients 1 h before
CPT and 10 min following a positive CPT response, and in
healthy subjects after the highest provocation dose [27]. All
samples were collected in both eyes without previous topical
anesthesia, as previously described. Briefly, dry Sharp-tip
Microsponges  (Alcon  Lab.  Inc.,  Fort  Worth,  TX)  were
inserted at the same time in the inferior conjunctival fornix,
removed after 30 s and then immediately immersed in a 1.5 ml
vial  containing  50  μl  of  tissue  protein  extractor  solution
(TPER; Pierce, Rockford, IL) with cocktail protease inhibitors
TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH ALLERGIC CONJUNCTIVITIS INCLUDED IN THE STUDY.
Patients (n) 15
Sex (n)
Male 9
Female 6
Age (years)
Range 20–51
Mean±SD 30±8
Atopic associated diseases (n)
Rhinitis 9
Asthma 2
Dermatitis 0
Skin PRICK test (n)
Graminacee 11
Parietaria 8
Dermatophagoides 4
Conjunctival provocation test (n)
Graminacee 7
Parietaria 5
Dermatophagoides 3
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48(Pierce). Microsponges were then centrifuged at 20,000× g
relative centrifugal force for 3 min to recover tears [28]. The
protein profile of tears collected was recorded according to
the A280 program (NanoDrop Technology, Wilmington, DE) .
Specific ELISA (Phoenix Pharmaceuticals Inc. Burlingame,
CA; detection limit: 0.09 ng/ml NPY, 0.07 ng/ml SP, 0.28ng/
ml  CGRP  0.12  ng/ml  VIP)  were  performed  on  extracted
proteins to quantify the amount of neuropeptides, according
to the manufacturer’s instructions.
The non-parametric Mann–Whitney U-test was used to
compare tear levels of neuropeptides between allergic and
healthy patients. Wilcoxon rank test was used to compare CPT
scores and neuropeptide levels before and after CPT with
allergen and with diluent. Neuropeptide levels at baseline and
after  challenge  were  also  compared  between  the  groups
challenged with allergen and with diluent alone. (SPSS 15,
Chicago, IL) Data are presented as mean±standard deviation
(SD)  from  mean  and  a  p  value  <0.05  was  considered
statistically significant.
RESULTS
All neuropeptides were detected in tears of healthy subjects:
SP=2.1±1.4 ng/ml; CGRP=6.7±2.3 ng/ml; NPY=3.5±1 ng/
ml;  VIP=5±3.8  ng/ml.  No  significant  differences  in
neuropeptide tear levels were observed between healthy and
allergic  patients  at  baseline:  SP=3.4±1.5  ng/ml;
CGRP=5.3±2.3  ng/ml;  NPY=3.1±1.3  ng/ml;  VIP=4.1±1.4
ng/ml (Figure 1).
All allergic patients (100%) showed positive conjunctival
reaction to CPT at a mean threshold dose of 1.7±3.1 BU/ml,
evidenced by a significant increase of total CPT score (0
versus 3.9±1; p=0.001), itching (0 versus 1.5±0.6; p=0.026),
and  hyperemia  (mean:  0  versus  2.2±0.5;  p=0.023).  No
significant changes in tearing were observed (mean: 0 versus
0.2±0.4; p=NSS). No conjunctival reaction was observed in
the control eyes challenged with vehicle (diluent) alone and
in all the healthy subjects challenged with allergen.
Mean  tear  levels  of  SP,  CGRP,  and  VIP  were
significantly  higher  after  CPT  (SP=3.9±1.3  ng/ml  versus
5.8±1.1 ng/ml, respectively, p=0.011; CGRP=5.5±2.3 ng/ml
versus  7.3±2.7  ng/ml;  p=0.002;  VIP=4±0.9  ng/ml  versus
5.1±1.5  ng/ml,  p=0.007).  NPY  tear  levels  showed  no
significant  changes  before  and  after  CPT  as  compared  to
baseline values (2.7±0.4 versus 3.3±1.3 ng/ml, respectively,
p=NSS; Figure 2). As compared to baseline, substance P was
increased in 100% of the tear samples taken after allergen
challenge, CGRP in 80%, VIP in 86%, and NPY in 62%. No
significant differences in SP, CGRP, NPY, and VIP tear levels
were detected in the control eyes before and after challenge
with  diluent  (SP=4±1.2  ng/ml  versus  4.8±2.2  ng/ml,
respectively, p=NSS; CGRP=5.9±2.8 ng/ml versus 6.6±2.7
ng/ml; p=NSS; NPY=3.3±1.8 ng/ml versus 3.4±2.3 ng/ml,
p=NSS; VIP=4.6±1.8 ng/ml versus 4.8±2.6 ng/ml, p=NSS).
No significant changes were observed at baseline and after
CPT in SP, CGRP, NPY, and VIP tear levels between eyes
challenged with allergen and eyes challenged with diluent.
Substance P, CGRP, NPY, and VIP tear levels in healthy
subjects  showed  no  changes  before  and  after  CPT
(SP=3.1±0.5  ng/ml  versus  3.4±1.5  ng/ml,  respectively,
p=NSS; CGRP=6.8±3.7 ng/ml versus 7±4 ng/ml; p=NSS;
NPY=3.6±1  ng/ml  versus  3.6±0.8  ng/ml,  p=NSS;
VIP=5.4±4.1 ng/ml versus 5.4±2.9 ng/ml, p=NSS).
DISCUSSION
In this study we demonstrate that neuromediators are normally
present in tears of healthy subjects, and that SP, CGRP, and
VIP are increased after conjunctival allergen challenge in
allergic patients.
The presence of neuromediators in normal conditions
indicates that they may play a role in maintaining the ocular
surface homeostasis. In line with this hypothesis, evidence
from recent studies indicates that neuropeptides are involved
in  regulation  of  tear  production  from  lacrimal  grand  and
mucous  secretion  from  conjunctival  goblet  cells  [29].
Moreover, neuropeptides are also known to cooperate with
Figure 1. SP, CGRP, NPY, and VIP are
present in tear fluid of healthy subjects
and their values do not differ from those
of allergic patients in non-active phase.
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49innate immunity for the protection of ocular surface structures
from pathogens and mechanical damage [22,30].
In this study we also show that SP, CGRP, and VIP are
normally present in tears of allergic subjects and increase after
conjunctival allergen challenge. It is unclear whether these
changes represent a pathogenic mechanism of the allergic
reaction or a mere epiphenomenon of the disease. Previous
data from other groups support the hypothesis that changes in
neuropeptide levels are involved in the pathogenesis of the
allergic  reaction.  Specifically,  an  increase  of  SP  tear  and
plasma levels has been described in patients with VKC [24]
and  increased  SP  tear  levels  were  also  demonstrated  in
patients with seasonal allergic conjunctivitis [23]. Our results
show a significant increase of SP, CGRP, and VIP tear levels
after challenge with allergen –but not with diluent– and no
significant changes at baseline and after challenge between
CPT  eyes  and  control  eyes.  The  similarity  of  mean
neuropeptide levels before and after challenge with allergen
and  with  diluent,  apparently  in  contrast  with  our  results
showing a significant increase in the CPT group only, may be
explained by the high variability in tear neuropeptide levels
observed  among  individuals.  However,  using  a  “paired
Wilcoxon Rank test” for statistical analysis –which analyses
the magnitude of the difference in paired samples– allowed us
to convincingly demonstrate the increase of SP, CGRP and
VIP  tear  levels  after  CPT  only  in  eyes  challenged  with
allergen.
In our study, no differences were found in SP, CGRP,
NPY,  and  VIP  tear  levels  of  asymptomatic  patients  with
allergic conjunctivitis and healthy non-allergic subjects. A
possible explanation to this finding is that all allergic patients
included in our study were selected for being in a non-active
phase  –out  of  allergy  season–,  with  no  active  signs  and
symptoms of allergic conjunctivitis at the time of inclusion.
However, when these allergic patients were challenged with
allergen by CPT, they showed a conjunctival allergic reaction
characterized by itching and redness, paralleled by an increase
of  neuropeptide  tear  levels.  Based  on  these  results,  we
hypothesize conjunctival itching, hyperemia and chemosis
during the allergic reaction could be influenced by locally
released neuromediators. In line with this hypothesis, SP is
believed to induce histamine release and mucus secretion, and
to increase vascular permeability, while CGRP and VIP may
exert blood vessel vasodilatation, leukocyte extravasation and
cytokine secretion. Our findings are in line with evidence
demonstrating an increase of SP, CGRP, and VIP after nasal
allergen challenge and in airway hyperresponsiveness [16,
31,32]. In our study, NPY was not significantly increased after
conjunctival allergen challenge, suggesting a different role of
this neuromediator in the ocular surface immune reaction. The
role  of  NPY  in  allergic  reaction  is  still  largely  debated.
Previous studies showed that NPY induces vasoconstriction
and that local pre-treatment with exogenous NPY in a nasal
allergen  challenge  leads  to  a  reduction  of  both  nasal
obstruction  and  mucus  secretion,  suggesting  a  protective
effect of NPY on both vasodilation and secretory responses.
In conclusion, our study shows that neuropeptides are
present in tears and may play an active role in both healthy
and allergic conjunctiva. Locally released neuropeptides act
directly on the epithelia, blood vessels and immune cells,
potentially  modulating  protective  and  inflammatory
responses. Our preliminary data showing an imbalance of tear
neuropeptides during allergic reactions of the ocular surface
requires further studies to clarify the specific role of individual
neuropeptides  in  healthy  conditions  and  in  the  mucosal
response at different organ sites.
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